Belite Bio (BLTE) EBT (2022 - 2026)

Belite Bio's EBT history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.

• On a quarterly basis, EBT fell 88.68% year-over-year to -$26.9 million in Q1 2026; TTM through Mar 2026 was -$63.4 billion, a 123.99% decrease from a year earlier, with the FY2025 full-year figure at -$77.6 million, down 132.3% from the prior year.
• EBT grew to -$26.9 million in Q1 2026 per BLTE's latest filing, from -$25.3 billion in the prior quarter.
• Across five years, EBT topped out at -$6.8 million in Q4 2022 and bottomed at -$25.3 billion in Q4 2025.
• The 5-year median for EBT is -$6.8 billion (2023), against an average of -$7.4 billion.
• Across the five-year window, EBT sank 144371.46% in 2024 and soared 99.82% in 2025, its largest moves.
• Year by year, EBT stood at -$6.8 million in 2022, then decreased by 3.07% to -$7.0 million in 2023, then sank by 144371.46% to -$10.1 billion in 2024, then tumbled by 150.73% to -$25.3 billion in 2025, then jumped by 99.89% to -$26.9 million in 2026.
• Per Business Quant, the three latest BLTE EBT figures stand at -$26.9 million (Q1 2026), -$25.3 billion (Q4 2025), and -$21.7 billion (Q3 2025).